Shield Legal Network

Belviq® linked to Cancers

  • Pancreatic Cancer
  • Colorectal Cancer
  • Lung Cancer

Belviq® Weight Loss Supplement Linked To Cancers:

• Pancreatic Cancer 
• Breast Cancer
• Lung Cancer 
• Brain Cancer 
• Thyroid Cancer
• Other Cancers

YOU MAY BE ENTITLED TO COMPENSATION

By clicking the "SUBMIT" button, I consent to receive recurring auto dialed and/or pre-recorded telemarketing calls and/or text messages from Shield Legal LP or our partners in order to discuss my legal options and at the telephone number I provided. I also consent to the Shield Legal LP Privacy Policy and Terms of Use. I understand that I may receive a call even if my telephone number is listed on a Do Not Call list and that my consent is not a requirement of purchase. I understand that my telephone company may impose charges on me for these contacts and that I can revoke this consent at any time. For SMS campaigns: Text STOP to cancel and HELP for help. Msg & data rates may apply. Recurring msgs up to 9 msgs per month.

YOU OR A LOVED ONE MAY BE ELIGIBLE FOR A SETTLEMENT

In February 2020, the FDA issued a withdrawal notice for the weight-loss drug Belviq® (lorcaserin) and Belviq® XR after numerous follow-up studies found an increased risk of cancer development in users who took the drug.

According to multiple studies, more patients that took Belviq® were diagnosed with cancer than those who took a placebo. This led the FDA to ask the manufacturer to remove Belviq® from the market on February 13, 2020.

MILLIONS IN CORPORATE PROFITS MADE BY RISKING CONSUMER SAFETY

Why Belviq® Is Off Store Shelves

First approved by the FDA in 2012, Belviq® was sold as a prescription weight loss drug that helped give users the feeling of being "full". However, a 5-year study that examined 12,000 patients found that Belviq® and its long-acting form, Belviq® XR, may lead to an increased risk of developing certain cancers. 

The FDA soon announced that Belviq's® manufacturer, Eisai Inc.®,  has agreed to withdraw Belviq® and Belviq® XR from the marketplace. Now, many consumers allege that Belviq's® manufacturer knew of the dangers behind their drug, but failed to warn the public or health officials. 

sad-woman-6

THE FDA ISSUES A BELVIQ® RECALL DUE TO CANCER RISK –
FEBRUARY 2020 

FDA STATEMENT RELEASED STATING INCREASED CANCER RISK –
JANUARY 2020

CLINICAL FOLLOW-UP STUDIES ON BELVIQ® BEGIN –
JANUARY 2014

BELVIQ® BECOMES FDA APPROVED –
JUNE 2012

100% FREE CASE EVALUATION WITH EXPERIENCED & TRUSTED LAW FIRMS. SEE IF YOU QUALIFY TODAY!

ATTORNEY ADVERTISING. This Website is not intended to provide medical advice. Consult your doctor or physician before starting or stopping any medication.

Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Recoveries are not an indication of future results. Every case is evaluated on its own facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. Shield Legal does not itself provide legal services. Cases will be referred to third party attorneys and law firms. Do not rely on this advertisement in making any medical decision. Please call your physician before making any medical decision, including altering your use of any drug. Court costs and case expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement or dramatization, and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either express or implied. Anyone considering a lawyer should independently investigate the lawyers' credentials and ability, and not rely upon advertisements or self-proclaimed expertise.

Powered by

shiledlegalnetwork

© 2019 Shield Legal LP. All Rights Reserved.